التفاصيل البيبلوغرافية
| العنوان: |
Non-steroidal anti-inflammatory drug use is determined by disease activity in axSpA and decreased by biologicals: a longitudinal analysis. |
| المؤلفون: |
E. D., Ediboğlu, D., Solmaz, G., Kabadayı, S., Gücenmez, H., Cinaklı, E. O., Akat, M., Özmen, S., Akar |
| المصدر: |
ARP Rheumatology; Oct-Dec2023, Vol. 2 Issue 4, p322-329, 8p |
| مصطلحات موضوعية: |
NONSTEROIDAL anti-inflammatory agents, SPONDYLOARTHROPATHIES, TREATMENT of arthritis, C-reactive protein, DATA analysis |
| مستخلص: |
Objective: To evaluate non-steroidal anti-inflammatory drug (NSAID) use and Assessment in Spondyloarthritis International Society (ASAS)-NSAID scores in patients with axial spondyloarhritis (axSpA) in a longitudinal study. Methods: In total, 429 patients with axSpA (59% male; 64% with radiographic axSpA) were included in this study. Data regarding disease activity, C-reactive protein (CRP) levels, and NSAID use and dosage were collected at 0, 12, 24, and 52 weeks retrospectively. The relationship with NSAID use/ASAS-NSAID scores and other factors were tested using generalized estimating equations (GEE). Results: At baseline (week 0), 92.8% of patients in biologic disease-modifying anti-rheumatic drugs (bDMARDs) group and 82.1% of patients in conventional treatment group were being treated with NSAIDs. At baseline, the proportion (p=0.03) and the median (IQR) ASAS-NSAID scores were higher in bDMARDs group [100 (50-100) vs 50 (16.6-100); p<0.001]. During follow-up, NSAID use and ASAS-NSAID scores decreased significantly in patients treated with bDMARDs (p<0.001) and the reduction remained stable throughout the follow-up However, neither NSAID use (p=0.06) nor ASAS-NSAID scores changed in conventional treatment group (p=0.15). In bDMARDtreated patients, ASDAS-CRP and BASFI scores were independent determinants for NSAID use, and BASDAI and PGA were determinants for NSAID dosage. There was no independent significant predictor for ASAS-NSAID scores; PGA was the only significant predictor for NSAID use in the conventional treatment group. Conclusion: Biologic treatment was associated with low NSAID intake in patients with axSpA, and NSAID use was determined mainly by disease activity and partly by functional during bDMARD treatment. [ABSTRACT FROM AUTHOR] |
|
Copyright of ARP Rheumatology is the property of Sociedade Portuguesa de Reumatologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
Full Text Finder